Trean Insurance Group logo
Trean Insurance Group TIG

Annual report 2022
added 03-16-2023

report update icon

Trean Insurance Group Balance Sheet 2011-2026 | TIG

Annual Balance Sheet Trean Insurance Group

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-30.9 M -99.2 M -122 M -45.2 M -19.8 M - - - - - - -

Long Term Debt

77.1 M 30.4 M 31.6 M 7.4 M 7.3 M - - - - - - -

Total Liabilities

1.27 B 1.08 B 960 M 777 M 695 M - - - - - - -

Retained Earnings

62.4 M 128 M 113 M 40.4 M 9.78 M - - - - - - -

Total Assets

1.58 B 1.5 B 1.37 B 919 M 800 M - - - - - - -

Cash and Cash Equivalents

108 M 130 M 153 M 74.3 M 56 M - - - - - - -

Book Value

315 M 422 M 410 M 142 M 105 M - - - - - - -

Total Shareholders Equity

315 M 422 M 410 M - - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Trean Insurance Group

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 77.5 M 29.6 M 30 M 30.4 M 30.9 M 31.1 M 31.5 M 31.6 M 31.6 M 31.6 M 31.6 M 29 M 29 M 29 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- 1.18 B 1.1 B 1.08 B 1.08 B 1.03 B 988 M 943 M 960 M 960 M 960 M 960 M 772 M 772 M 772 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- 154 M 146 M 141 M 128 M 127 M 121 M 119 M 109 M 109 M 109 M 113 M 38.7 M 40.4 M 40.4 M - 11.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- 1.58 B 1.51 B 1.49 B 1.5 B 1.45 B 1.41 B 1.36 B 1.37 B 1.37 B 1.37 B 1.37 B 919 M 919 M 919 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- 81.5 M 101 M 104 M 130 M 138 M 114 M 131 M 157 M 153 M 153 M 153 M 74.3 M 74.3 M 74.3 M - 53.6 M - - - 45 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- 403 M 410 M 416 M 422 M 422 M 417 M 413 M 410 M 410 M 410 M 410 M 147 M 147 M 147 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- 403 M 410 M 416 M 422 M 422 M 417 M 413 M 410 M 410 M 410 M 410 M 142 M 132 M 126 M 118 M 105 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Trean Insurance Group, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BioNTech SE BioNTech SE
BNTX
- - $ 27.2 B germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
INmune Bio INmune Bio
INMB
$ 1.52 -1.3 % $ 37.6 M usaUSA
Exelixis Exelixis
EXEL
$ 48.7 9.64 % $ 13.2 B usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.48 -3.89 % $ 3.56 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
- - $ 71.1 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.15 1.19 % $ 655 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
- - $ 5.51 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.17 3.2 % $ 3.08 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.08 5.15 % $ 4.95 B schweizSchweiz
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.7 3.66 % $ 452 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Galapagos NV Galapagos NV
GLPG
$ 28.81 1.48 % $ 2.69 B belgiumBelgium
Genmab A/S Genmab A/S
GMAB
$ 27.89 1.34 % $ 17.2 B danmarkDanmark